Hypoglycemic and lipid lowering effects of theaflavins in high-fat diet-induced obese mice

TFs, TF1, TF2a and TF3 administered to HFD mice not only decreased the level of blood glucose and HOMA-IR but also activated the SIRT6/AMPK/SREBP-1/FASN pathway to inhibite synthesis and accumulation of the lipids in the liver to ameliorate obesity.